Dan Paterson

IQVIA, Inc. provides information technology solutions to the healthcare industry. It offers research and development, enterprise information management, commercial analytics, market analysis, patient consent system, content management, and other related solutions. The company was founded by Bill Frohlich and David Dubow in 1954 and is headquartered in Danbury, CT.

PharMetrics, Inc. provided healthcare market insights based on longitudinal and patient-centric information. The company was founded in 1998 and was headquartered in Watertown, MA.

The DNA Repair Co. develops cancer diagnostics solutions. The firm produces DNA Repair biomarkers which reveal therapeutic solutions for cancer drugs. The company was founded by Alan D’Andrea, William A. Haseltine, Michael B. Yaffe, and Markus Grompe and is headquartered in Boston, MA.

OnCare, Inc. was a oncology practice management and disease management company. The company provides management services to Texas Cancer Care. The company was headquarteerd in San Bruno, CA.

Axion Pharmaceuticals, Inc. provides cancer therapy products. It is headquartered in South San Francisco, CA.

Part of Aptiv Plc, CareTools, Inc. develops medical software. The company is based in Seattle, WA. The company was founded by Thomas C. Giannulli. CareTools was acquired by DPH Medical Systems LLC on June 29, 2005.

On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its circulating tumor cell technology will enable better decision-making across multiple cancers: improving the quality of life for patients and ultimately increasing survival. On-Q-ity's products and services are based on its unique and proprietary circulating tumor cell (CTC) technology which enables them to capture, count and characterize CTCs from a sample of patient blood. Through proprietary circulating tumor cell (CTC) and biomarker technology, they are creating products designed to non-invasively monitor and optimize cancer care throughout the disease cycle. They invite companies with complementary technologies, innovative biomarkers, and special expertise in its field to explore partnering relationships.